✦ LIBER ✦

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

✍ Scribed by Ikeda, Masafumi; Shiina, Shuichiro; Nakachi, Kohei; Mitsunaga, Shuichi; Shimizu, Satoshi; Kojima, Yasushi; Ueno, Hideki; Morizane, Chigusa; Kondo, Shunsuke; Sakamoto, Yasunari; Asaoka, Yoshinari; Tateishi, Ryosuke; Koike, Kazuhiko; Arioka, Hitoshi; Okusaka, Takuji

Book ID: 125358950
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 403 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-014-0109-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II trial of the oral antiangio

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

✍ Fumihiko Kanai; Haruhiko Yoshida; Ryosuke Tateishi; Shinpei Sato; Takao Kawabe; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 408 KB

Phase I/II study of the pharmacokinetics

Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma

✍ Junji Furuse; Takuji Okusaka; Shuichi Kaneko; Masatoshi Kudo; Kohei Nakachi; Hid 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Safety and efficacy of sunitinib in pati

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

✍ Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 178 KB

1208 POSTER Phase I and Pharmacokinetic

1208 POSTER Phase I and Pharmacokinetic Study of the Angiogenesis Inhibitor TSU-68 Combined With Carboplatin Plus Paclitaxel in Patients (pts) With Advanced Non-small-cell Lung Cancer (NSCLC)

✍ H. Yoshioka; I. Okamoto; K. Takeda; M. Satouchi; N. Yamamoto; T. Seto; K. Kasaha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

43 POSTER Assessment of predictive biolo

43 POSTER Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC)

✍ T. Okusaka; F. Kanai; M. Ikeda; C. Morizane; H. Yoshida; R. Tateishi; S. Shiina; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Efficacy of the combination of long-acti

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

✍ Verset, G; Verslype, C; Reynaert, H; Borbath, I; Langlet, P; Vandebroek, A; Peet 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 153 KB